Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
POSTER: MM-1485 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir Vorobyev, Michèle Cavo, Kazuhito Suzuki, Paweł Robak, Kristin Morris, Chee Paul Lin, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet E. Manasanch, Brandon E. Kremer, MariaVictoria Mateos, Meletios A Dimopoulos (2025). POSTER: MM-1485 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01371-0.
Article18 days agoEfficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.
Marcelo Pitombeira de Lacerda, Meletios A Dimopoulos, Luděk Pour, Kihyun Kim, Sergey Voloshin, Hanlon Sia, Esther González, Chang‐Ki Min, Anna Sureda, Ivan Spicka, Paweł Robak, Marek Hus, Vera Zherebtsova, Merit Hanna, Vinay Jadhav, Nicholas Pirooz, Ianire Garrobo-Calleja, Lydia Eccersley, Vânia Hungria, Meral Beksaç (2025). Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7548.
Article18 days agoMM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir Vorobyev, Michèle Cavo, Kazuhito Suzuki, Paweł Robak, Kristin Morris, Chee Paul Lin, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet E. Manasanch, Brandon E. Kremer, MariaVictoria Mateos, Meletios A Dimopoulos (2025). MM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02742-9.
Article18 days agoDaratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Peter M. Voorhees, Meletios A Dimopoulos, Yaël C. Cohen, Fredrik Schjesvold, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksaç, Keith Stockerl‐Goldstein, Hila Magen, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Simon Hallam, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Abdullah Khan, Eva Medvedova, J Christine Ye, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Diego Vieyra, Abid Raval, Linlin Sha, Liang Li, Els Rousseau, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2025). Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-372.
Article18 days agoIsatuximab for the treatment of multiple myeloma: current clinical advances and future directions
Paul G. Richardson, Elisabeth K. O’Donnell, Peter O’Gorman, Lisa Leypoldt, Jacob P. Laubach, Francesca Gay, Xavier Leleu, Thierry Façon, Philippe Moreau, Meletios A Dimopoulos, Hartmut Goldschmidt, K. Elias, Michèle Cavo, Katja Weisel, Jesús G. Berdeja, Robert Z. Orlowski, Meral Beksaç, Aurore Perrot, Joseph Mıkhael, T. John Martin (2025). Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions. , 34(7-8), DOI: https://doi.org/10.1080/13543784.2025.2532446.
Article18 days ago